S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

Behavioral Melanoma Prevention Project

Sponsor
HackensackUMC

Protocol Number
HackensackUMC 2017-0270 (SUNTALK JR)

To Learn More Call
201-510-0910

A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091202

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910